Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Out of 33 TGCA studies, the effects of TP53 mutations were statistically significant in nine cancers (lung adenocarcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, acute myeloid leukemia, clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, uterine endometrial carcinoma, and thymoma) for survival time and in five cancers (pancreatic adenocarcinoma, hepatocellular carcinoma, chromophobe RCC, acute myeloid leukemia, and thymoma) for disease-free survival time. 30542790 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease CTD_human A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 24974848 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE LOHs were also seen at the adenomatous polyposis coli (APC) locus (5q21-22) in subsets of these thymomas, whereas combined LOHs at the APC, retinoblastoma (13q14.3), and p53 (17p13.1) loci were confined to a subset of B3 thymomas that had possibly evolved from APC-hemizygous B2 thymomas by tumor progression; indeed, thymomas combing B2 plus B3 features are common. 12839963 2003
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE The incidence of p53 low and high expressor in thymoma were 19% (5/26) and 8% (2/26), respectively. p53 immunopositivity in thymoma was significantly correlated with PCNA labeling index (LI). p53 expression ratio in invasive thymoma (33%) tended to be higher than that in non-invasive thymoma (18%). p53 expression was detected in one of the thymic carcinoma. 9852302 1998
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Histological and clinical evaluation and also p53 analysis revealed three major tumour groups: non-organotypic thymic carcinomas with frequent p53 alterations (7/9) and occurrence of p53 gene mutations (2/9); malignant thymomas with frequent p53 alterations but without p53 gene mutations (11/18); and benign thymomas with rare p53 alterations and without p53 gene mutations (2/17). 9247629 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Our data suggest that, unlike other more common cancers, alteration of the p53 gene may not play a significant role in the tumorigenesis of thymoma. 9398039 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE There was significant difference in p53 protein immunopositivity between thymic carcinoma and each of the noninvasive or invasive/metastatic thymomas. 7572785 1995
Entrez Id: 8314
Gene Symbol: BAP1
BAP1
0.310 Biomarker disease BEFREE Genes in histone modification [BAP1 (n = 6; 13%), SETD2 (n = 5; 11%), ASXL1 (n = 2; 4%)], chromatin remodeling [SMARCA4 (n = 2; 4%)], and DNA methylation [DNMT3A (n = 3; 7%), TET2 (n = 2; 4%), WT1 (n = 2; 4%)] pathways were recurrently mutated in TCs, but not in thymomas. 25482724 2014
Entrez Id: 8314
Gene Symbol: BAP1
BAP1
0.310 Biomarker disease CTD_human A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 24974848 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.310 Biomarker disease CTD_human A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 24974848 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.310 GeneticVariation disease BEFREE A polymorphism in the 3' untranslated region of exon 3 of CDKN2 was detected in 5 cases of thymoma. 9398039 1997
Entrez Id: 1540
Gene Symbol: CYLD
CYLD
0.300 Biomarker disease CTD_human A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 24974848 2014
Entrez Id: 55193
Gene Symbol: PBRM1
PBRM1
0.300 Biomarker disease CTD_human A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 24974848 2014
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR "When a thymic carcinoma ""becomes"" a GIST." 23375402 2013
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254 2012
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 Biomarker disease BEFREE KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, while also serving as a predictor of prognosis for TETs. 22938452 2012
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. 20970876 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Large-scale analysis of KIT aberrations in Chinese patients with melanoma. 21325067 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. 21969494 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 GeneticVariation disease BEFREE Considering the need to treat advanced TC more effectively, disparate findings in predictive molecular markers (eg, KIT mutations in TSCC, but not in thymomas) suggest that targeted treatments will have to be different in thymomas and TC. 21070984 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 Biomarker disease BEFREE Apart from their different morphology, TC and thymomas differ also in functional terms (TC, in contrast to thymomas, have lost the capacity to promote the maturation of intratumorous lymphocytes), have different genetic features (discussed in this review), a different immunoprofile (most TC overexpress c-KIT, whereas thymomas are consistently negative), and different clinical features (TC, in contrast to thymomas, are not associated with paraneoplastic myasthenia gravis). 20859121 2010
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. 20736294 2010
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. 19461405 2009
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. 19861435 2009
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. 20197733 2009